HCPLive Podcasts

A recent episode of the Joint Ventures podcast previewed six abstracts for ACR Convergence 2026, held November 6 to 11 in Orlando, Florida. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, each selected three from nearly 3,000 abstracts. Their picks span checkpoint inhibitor arthritis, psoriatic arthritis biomarkers, novel imaging, JAK inhibitor prescribing, and tissue-level B-cell depletion.

Gout remains poorly managed at the population level despite a well-understood pathophysiology, established serum urate targets, and an expanding pharmacological toolkit, according to a recent episode of the rheumatology podcast Joint Ventures. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, reviewed current guidelines, emerging trial data, and the pipeline in gout management.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.Studies featured in this episode include: AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)  CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341) Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048) BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001) 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341) JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005) Click here to read more and watch the full video at RheumatologyLive.

Could hepatitis B finally have a finite treatment option? Tatyana Kushner, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to break down the phase 3 B-Well data for bepirovirsen, the first agent to hit functional cure as a primary endpoint in chronic hepatitis B.The conversation covers the phase 3 B-Well 1 and B-Well 2 results, published in the New England Journal of Medicine and presented at EASL 2026, and why quantitative HBsAg testing is becoming essential to patient selection ahead of a potential approval. Kushner, Reau, and Brown also work through what functional cure actually means for patients, how it compares to spontaneous HBsAg loss, and what dosing and monitoring are likely to look like given signals for ALT elevation and renal effects seen in the trials. They discuss which patients are unlikely to be candidates, including those with cirrhosis or decompensated liver disease, and close with a look at what an approval could mean for hepatitis B screening rates and referral patterns between primary care and specialty hepatology.Bepirovirsen is not yet FDA approved. The FDA has accepted the New Drug Application for priority review, with a PDUFA goal date of October 26, 2026.For more: https://www.hcplive.com/view/liver-lineup-bepirovirsen-and-the-push-toward-functional-cure-in-hepatitis-b

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).Topics covered:Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to changeThe diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementationThe recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question10 mg vs. 2 mg dose considerations and off-treatment response dataPhase 3 pipelineFor more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline

In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.Click here to watch the episode.

The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.Click here to watch the episode.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.Click here to watch the episode.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed.The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.